Overview

Comparative Bioavailability in Healthy Elderly Volunteers

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
A randomised four way crossover design in which each subject will receive two dose levels of TRx-0037 and two doses of TRx-0014 over approximately a four week period in randomised order.
Phase:
Phase 1
Details
Lead Sponsor:
TauRx Therapeutics Ltd
Collaborator:
Quotient Clinical